Free Trial

Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 6.6% - Should You Sell?

Maze Therapeutics logo with Medical background

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares traded down 6.6% on Wednesday . The company traded as low as $14.00 and last traded at $14.06. 67,075 shares changed hands during mid-day trading, a decline of 68% from the average session volume of 211,837 shares. The stock had previously closed at $15.06.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Guggenheim restated a "buy" rating and set a $19.00 price target on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. Wedbush began coverage on Maze Therapeutics in a research report on Tuesday. They issued an "outperform" rating and a $17.00 target price for the company. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $23.50.

Read Our Latest Stock Report on MAZE

Maze Therapeutics Stock Performance

The firm's 50 day moving average is $11.46.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.39).

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MAZE. New York State Common Retirement Fund bought a new position in shares of Maze Therapeutics in the first quarter valued at approximately $25,000. Corebridge Financial Inc. bought a new position in Maze Therapeutics in the 1st quarter valued at $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Maze Therapeutics during the 1st quarter valued at $57,000. Rhumbline Advisers bought a new position in shares of Maze Therapeutics in the first quarter worth $80,000. Finally, Deutsche Bank AG bought a new position in shares of Maze Therapeutics in the first quarter worth $98,000.

Maze Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

Read More

Should You Invest $1,000 in Maze Therapeutics Right Now?

Before you consider Maze Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.

While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines